Comparison of topical tacrolimus 0.1 % in pectin ointment with clobetasol 0.5% ointment in adults with moderate to severe desquamative gingivitis: A 4-week, randomized, double-blind clinical trial

Clinical Therapeutics

Volumn 28, Issue 9, 2006, Pages 1296-1302

  Corrocher, Giovanni ^a   Di Lorenzo, Gabriele ^b   Mansueto, Pasquale ^b   Martinelli, Nicola ^a   Esposito Pellitteri, Maria ^b   Gelio, Stefano ^c   Lombardo, Giorgio ^a   Luisa Pacor, Maria ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c Servizio Farmacia del Policlinico G B Rossi di Verona   (Italy)

Author keywords

clobetasol; desquamative gingivitis; tacrolimus

Indexed keywords

CLOBETASOL; PECTIN; TACROLIMUS;

ADULT; AGE DISTRIBUTION; AGED; APPLICATION SITE BURNING; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATIVE GINGIVITIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; EVALUATION; FEMALE; GINGIVA DISEASE; GINGIVITIS; HEART RATE; HUMAN; MALE; MONOTHERAPY; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; URINALYSIS; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ADULT; AGED; CLOBETASOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GINGIVITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; PECTINS; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 33750050547     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.09.022     Document Type: Article

References (36)

1. Robinson N.A., and Wray D. Desquamative gingivitis: A sign of mucocutaneous disorders-a review. Aust Dent J 48 (2003) 206-211
2. Prinz H. Chronic diffuse desquamative gingivitis. Dentol Cosmos 74 (1932) 331-333
3. Meritt A.H. Chronic desquamative gingivitis. J Periodontol 4 (1933) 30-34
4. [in French]. Vaillant L., Chauchaix-Barthes S., Huttenberger B., et al. Chronic desquamative gingivitis syndrome: Retrospective analysis of 33 cases. Ann Dermatol Venereol 127 (2000) 381-387
5. Scully C., and Porter S.R. The clinical spectrum of desquamative gingivitis. Semin Cutan Med Surg 16 (1997) 308-313
6. Chandra R.V., Pandurang P., and Bhat K.M. Labial veneers in the management of desquamative gingivitis: Report of a case. J Contemp Dent Pract 5 (2004) 122-132
7. Lener E.V., Brieva J., Schachter M., et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 137 (2001) 419-422
8. Olivier V., Lacour J.P., Mousnier A., et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: An open prospective study. Arch Dermatol 138 (2002) 1335-1338
9. Jones L.E., and Dolby A.E. Desquamative gingivitis associated with psoriasis. J Periodontol 43 (1972) 35-37
10. Wray D. Pyostomatitis vegetans. Br Dent J 157 (1984) 316-318
11. Porter S.R., Scully C., Midda M., and Eveson J.W. Adult linear immunoglobulin A disease manifesting a desquamative gin givitis. Oral Surg Oral Med Oral Pathol 70 (1990) 450-453
12. Reich K., Vente C., and Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 139 (1998) 755-757
13. Schuppe H.C., Homey B., Assmann T., et al. Topical tacrolimus for pyoderma gangrenosum. Lancet 351 (1998) 832
14. Ruzicka T., Assmann T., and Homey B. Tacrolimus: The drug for the turn of the millennium?. Arch Dermatol 135 (1999) 574-580
15. Richter-Hintz D., Schuppe H.C., Homey B., et al. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 42 (2000) 304-305
16. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report. J Am Acad Dermatol 44 (2001) 995-998
17. Yamamoto T., and Nishioka K. Topical tacrolimus: An effective therapy for facial psoriasis. Eur J Dermatol 13 (2003) 471-473
18. Bamford J.T., Elliott B.A., and Haller I.V. Tacrolimus effect on rosacea. J Am Acad Dermatol 50 (2004) 107-108
19. Anderson B.E., Marks Jr. J.G., and Mauger D.T. Efficacy of tacrolimus ointment in the prevention and treatment of contact dermatitis. Dermatitis 15 (2004) 158-159
20. Pacor M.L., Di Lorenzo G., Martinelli N., et al. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study. Clin Exp Allergy 34 (2004) 639-645
21. Available at:. Schachner L.A., Lamerson C., Sheehan M.P., et al., USTacrolimus Ointment Study Group. Tacrolimus oint ment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, doubleblind, vehicle-controlled study. Accessed September 2005. Pediatrics 116 (2005) e334-e342. http://pediatrics.aapublications.org/cgi/content/full/116/3/e334
22. Beck L.A. The efficacy and safety of tacrolimus ointment: A clinical review. J Am Acad Dermatol 53 Suppl 2 (2005) 5165-5170
23. Nazzaro G., and Cestari R. Topical tacrolimus ointment in ulcerative lichen planus: An alternative thera peutic approach. Eur J Dermatol 12 (2002) 321
24. Morrison L., Kratochvil III F.J., and Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 47 (2002) 617-620
25. Hodgson T.A., Sahni N., Kaliakatsou F., et al. Long-term efficacy and safety of topical tacrolimus in the man agement of ulcerative/erosive oral lichen planus. Eur J Dermatol 13 (2003) 466-470
26. Tocci M.J., Matkovich D.A., Collier K.A., et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143 (1989) 718-726
27. Panhans-Gross A., Novak N., Kraft S., and Bieber T. Human epidermal Langerhans' cells are targets for the immuno suppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 107 (2001) 345-352
28. Lyon C.C., Stapleton M., Smith A.J., et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatol Treat 12 (2001) 13-17
29. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Bio medical Research Involving Human Subjects. Accessed October 2004 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net/e/policy/b3.htm Accessed October 2004
30. [EMEA Web site]. European Agency for the Evaluation of Medicinal Products. Accessed July 1996. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed July 1996.
31. Armitage P., Berry G., and Matthews J.N. Statistical Methods in Medical Research. 4th ed. (2002), Blackwell Science, Oxford, UK
32. Altman D.G. Statistics and ethics in medical research: III. How large a sample?. BMJ 281 (1980) 1336-1338
33. Lo Muzio L., della Valle A., Mignogna M.D., et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: A clinical and pilot study on 54 patients. J Oral Pathol Med 30 (2001) 611-617
34. Gonzalez-Moles M.A., Ruiz-Avila I., Rodriguez-Archilla A., et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95 (2003) 688-692
35. Rozycki T.W., Rogers III R.S., Pittelkow M.R., et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. J Am Acad Dermatol 46 (2002) 27-34
36. Vente C., Reich K., Rupprecht R., and Neumann C. Erosive mucosal lichen planus: Response to topical treatment with tacrolimus. Br J Dermatol 140 (1999) 338-342